Burris served as president of ASCO in 2019-2020 and is serving as Chair of the Board for the 2020-2021 term. He has authored over 400 publications and 700 abstracts.ĭr. In 1997, he established in Nashville the first community – based early phase drug development program, which grew into the Sarah Cannon Research Institute. He is an associate of Tennessee Oncology, PLLC, where he practices medical oncology.ĭr. Burris’ clinical research career has focused on the development of new cancer agents with an emphasis on first – in – human therapies, having led the trials of many novel antibodies, small molecules, and chemotherapies now FDA approved. “Skip” Burris III, MD, FASCO, FACP serves as president and chief medical officer of Sarah Cannon, as well as the executive director, drug development for Sarah Cannon Research Institute. “Skip” Burris III, MD, FASCO, FACP Chief Medical Officer, Sarah Cannon, Executive Director, Drug Development, Sarah Cannon Research Institute Pharmacogenomics & Pharmacovigilance in Precision Medicine.International Conference on Newborn Sequencing.Updates in Precision Medicine: Pharmacogenomics and Pharmacovigilance.
0 kommentar(er)
